Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
Tanabe Pharma said on October 29 that it has filed for the Japanese approval of its lymphoma drug candidate loncastuximab tesirine, known as Zynlonta overseas, while striking a deal with Nippon Shinyaku to commercialize the therapy in Japan. Under an…
To read the full story
Related Article
- Zynlonta Hits Primary Endpoint in Japanese PI/II Study: Tanabe
January 30, 2026
- Mitsubishi Tanabe Earns Japan Rights for ADC Zynlonta
January 19, 2022
BUSINESS
- Nipro Eyes 50-60 Stemirac Treatment Sites across Japan after Full Nod
November 20, 2026
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- Japan Drug Makers’ Sales Seen Dipping in FY2026 on Co-Marketing Exits
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026





